According to the American Society for Radiation Oncology's 2010 report, approximately 75% of oncology patients opt for radiation therapy. The primary aim of radiation therapy is to irradiate the tumor cells; however, the normal cells being exposed to the radiation therapy get damaged. Normal tissue cells are capable of self-repair, but repetitive damage reduces the reparation properties of normal cells. Factors that increase the risk and severity of skin reactions include high daily cumulative radiation doses, the type of beam utilized for irradiation, a large treatment field, treatment of areas with skin folds, and whether the radiation was given with chemotherapy.
The various products studied for this study include topical, oral, and dressing. Topical drugs are further classified as antibiotics, hydrophilic creams, corticosteroids, and others. Dressings are categorized as no-string barrier films, honey-impregnated gauze, hydrogel and hydrocolloid dressings, silicone-coated dressings, and others. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.The global radiodermatitis market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa markets.
Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global radiodermatitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global radiodermatitis market. The major players in the radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc, Stratpharma AG, and 3M Healthcare.
Based on product types, the global radiodermatitis market is categorized into:
Topical
Antibiotics
Hydrophilic Creams
Corticosteroids
Others
Dressing
No-string barrier films
Honey-impregnated gauze
Hydrogel and hydrocolloid dressings
silicone-coated dressings
Others
The radiodermatitis market is driven by factors such as the rising prevalence of cancer, with patients opting for radiation therapy and technological advancements in the drug formulation, such as hydrocolloids and hydrogels, which expedite healing with minimal pain. In addition, rising physician awareness regarding disease etiology and increasing online marketing with the affordable sale and purchase options will propel the market penetration of treatments. In 2016, the topical segment held the largest market share, chiefly due to factors such as corticosteroids, which are considered the gold standard for the treatment of radiodermatitis, and hydrophilic creams, which minimize the patient's discomfort by providing moisture to the dry desquamation skin area.
Dressings will be the fastest-growing segment throughout the forecast period of 2017–2025, primarily due to factors such as the rising prevalence of radiodermatitis and the wide range of dressings available as per the degree of skin complication due to radiation therapy. Hydrocolloid and hydrogel dressings are finding widespread use in the treatment of moist desquamation in order to promote a moist environment for reepithelization. The major players in the radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew Plc., Stratpharma AG, and 3M Healthcare.
For the purpose of this study, the global radiodermatitis market is categorized into the following regional and country-specific markets:
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Latin America
Brazil
Mexico
rest of Latin America
Middle East and Africa
GCC
Rest of the Middle East and Africa
North America will be the fastest-growing market for radiodermatitis throughout the forecast period of 2017–2025. According to the American Cancer Society, in 2017, about 1,688,780 new cancer cases were diagnosed. The dominance of North America is mainly attributed to the presence of key drivers such as the rising prevalence of cancer, the first treatment preference given to treat cancer being radiation therapy, and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the increasing prevalence of radiodermatitis and the rising fashion trend, which has resulted in a demand for radiation therapy to enhance the aesthetic appeal of personal beauty and an affordable reimbursement scenario.
Asia Pacific dominated the radiodermatitis market for the base year of 2016, and the factors that are anticipated to propel the market growth are the increasing number of chronic health complications resulting in demand for radiation therapy, the competitive market due to the presence of existing major and evolving players engaged in the manufacturing and sale of radiodermatitis products in these regions, increasing disposable incomes, and a supportive regulatory environment for radiodermatitis products. Moreover, factors such as developing healthcare infrastructure and extensive collaborations undertaken by pharmaceutical giants to expand their product portfolio in the untapped markets of developing areas with unmet medical needs are going to fuel the rapid growth of the radiodermatitis market in Latin America, the Middle East, and Africa in the near future.
Frequently Asked Questions:
The market for Radiodermatitis Market is expected to reach US$ 430.9 Mn By 2025.
The Radiodermatitis Market is expected to see significant CAGR growth over the coming years, at 4.18%.
The report is forecasted from 2017-2025.
The base year of this report is 2016.
Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc, Stratpharma AG, and 3M Healthcare. are some of the major players in the global market.
